Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04637256 · ClinicalTrials.gov registry record
Evaluation of Outcomes from Treatment of Benign or Malignant Gastroesophageal Diseases
A clinical trial of Pancreatic Malignant Neoplasm Primary, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04637256 is a study of Pancreatic Malignant Neoplasm Primary that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04637256, a study of Pancreatic Malignant Neoplasm Primary, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a retrospective chart review of patients who have been diagnosed with benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The Investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either the investigator's patients from their practice or through a national database. Data will be analyzed primarily by the study conductors.
Conditions Studied
Study Locations (1)
Texas
- Trinity Surgical Consultants, Methodist Richardson Medical Center - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2025-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04637256
The ClinicalTrials.gov registry entry for NCT04637256 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Malignant Neoplasm Primary appearing as the primary indexed condition, and to 0 interventions.
NCT04637256 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04637256 about?
NCT04637256 is a clinical study titled "Evaluation of Outcomes from Treatment of Benign or Malignant Gastroesophageal Diseases". This study will be a retrospective chart review of patients who have been diagnosed with benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The Investiga...
What is the current status of trial NCT04637256?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-03-06. Estimated completion is 2025-01-30.
What conditions does trial NCT04637256 study?
This clinical trial studies the following conditions: Pancreatic Malignant Neoplasm Primary.
Who is sponsoring clinical trial NCT04637256?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04637256 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.